Research roundup: week of Oct 5, 2026

[Peptides] · News from Oct 9, 2026

Why male immune systems may age faster: a thymus study in mice

A Mass General Brigham study, mostly in mice, tracked naive CD8 T cells (fresh "killer" T cells that haven't met a threat yet):

• Male mice lost them faster, with significantly fewer by middle age (9–12 months)
• Causes: early conversion into shorter-lived memory-like cells, plus androgen-linked thymus shrinkage limiting refill
• Male lymph nodes shrank sooner and recognized tumors less well
• Blocking androgens (surgery or degarelix) regrew the thymus and improved immunotherapy response; less so in aged mice
• Human data showed a similar sex pattern

Mostly mouse data. It doesn't show TRT harms immunity in men; hormone blockade was a lab tool, not advice.

Source: Nature Aging, Oct 9, 2026

[Hormones] · News from Oct 8, 2026

Menopause hormone therapy tied to more weight loss on semaglutide

A Mayo Clinic Florida study, to be presented at The Menopause Society's Oct 20-24 meeting, looked back at women over 45 with a BMI above 27:

• Nearly 2,400 on semaglutide, nearly 1,500 on tirzepatide
• Semaglutide: women also on hormone therapy lost significantly more weight, and it was sustained
• Tirzepatide: more loss early on, but the final difference wasn't statistically significant
• No weight-loss percentages released yet

A conference abstract, not yet a peer-reviewed paper, and observational, so it can't show cause. The lead author stressed weight loss isn't a reason to start hormone therapy; prospective trials are needed.

Source: The Menopause Society, Oct 8, 2026

Our guides: Semaglutide · Tirzepatide

[Peptides] · News from Oct 7, 2026

Report: a temporary pathway for some unapproved peptides

The Washington Post reports, citing two people familiar with the matter, that the administration is drafting a plan to let some compounding pharmacies temporarily dispense certain previously restricted peptides while new rules are written:

• The report didn't say which peptides, or when
• July: an FDA advisory panel backed six for the compounding list (BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon)
• FDA's own scientists had advised against them
• The vote is non-binding; FDA hasn't adopted it

Not announced and could change. A stopgap would not be FDA approval, and the gaps in human safety and effectiveness data would remain.

Source: The Washington Post, Oct 7, 2026

Our guides: BPC-157 · TB-500 · MOTS-c · Semax · KPV · Epitalon

[Regulatory] · News from Oct 7, 2026

KFF compares TrumpRx cash prices with 11 other wealthy countries

A KFF analysis, covered by NBC News, compared 32 brand-name TrumpRx drugs with no generic against public prices in 11 wealthy countries (prices from late August).

• 17 were cheaper than the average abroad; 15 were pricier
• Lowest of any country for 5; highest for 13
• Ozempic: $349 on TrumpRx; the highest price in the other countries was $190 a month
• Enbrel: $3,354 vs a $641 average abroad; Rydapt: $2,909 vs $5,901 in France, the lowest abroad

Caveats: public prices may miss confidential discounts, and TrumpRx spending doesn't count toward copays or deductibles. CMS didn't immediately comment.

Source: NBC News, Oct 7, 2026

Our guides: Semaglutide · Ozempic (semaglutide)

[GLP-1] · News from Oct 7, 2026

WHO's first child obesity guidelines: no weight-loss drugs under 10

WHO issued its first global guidelines on child and adolescent obesity:

• Ages 0–9: WHO does not recommend medicines, bariatric surgery or weight-loss devices
• Ages 10–19: approved medicines may be considered only when a supervised lifestyle programme hasn't worked
• Surgery may be considered for teens with severe obesity, under strict conditions
• Diet, activity and behaviour programmes: strongly recommended
• Context: 170 million kids aged 5–19 had obesity in 2024; prevalence 2% → 8% since 1990

This is guidance, not regulation; national approvals still apply. The release names no specific drugs (e.g. GLP-1s) and doesn't discuss side effects.

Source: World Health Organization, Oct 7, 2026

[Hormones] · News from Oct 7, 2026

Testosterone after menopause tied to more heart and stroke events

A study previewed by The Menopause Society ahead of its Oct 20-24 meeting compared postmenopausal women 45+ who started testosterone with matched women who didn't:

• 6,300+ propensity-matched women from US health records; prior cardiovascular disease excluded
• Average follow-up: nearly 3 years
• Heart disease, stroke, arterial blockage or heart failure: 3.8% on testosterone vs 0.5% without
• Hazard ratio 8.08; the authors note absolute rates were low

It's an observational conference abstract, so it can't rule out differences in who gets prescribed testosterone. No testosterone product is FDA-approved for women in the US.

Source: The Menopause Society, Oct 7, 2026

Our guides: Testosterone Cypionate

[GLP-1] · News from Oct 6, 2026

Do GLP-1s slow aging? Novo and Lilly share aging-clock data

At an aging-research meeting in Boston, Novo Nordisk and Eli Lilly shared molecular 'aging clock' data on their GLP-1 drugs:

• Novo (semaglutide): in blood from 10,052 people, the drug group read about 2 to 3 years younger than placebo on protein-based clocks
• A heart-protein clock showed a gap of up to 4 years
• Lilly (tirzepatide): a smaller study with DNA-based clocks found molecular aging mostly ran slower on the drug
• ARPA-H has put $38M into a study of semaglutide in healthy people over 60

These are company results shown at a conference. Experts say no one knows yet if this holds in healthy, lean people, and GLP-1s have side effects such as muscle loss.

Source: MIT Technology Review, Oct 6, 2026

Our guides: Semaglutide · Tirzepatide

[Hormones] · News from Oct 6, 2026

Estrogen-only HRT tied to slightly more autoimmune disease than combined HRT

A study to be presented at The Menopause Society's meeting (Oct 20-24) compared two types of systemic menopausal hormone therapy:

• Nearly 110,000 women from US health records, matched 1:1
• Any autoimmune disease (20 tracked): 4.9% vs 4.5%, estrogen-only vs estrogen plus progestogen
• Hazard ratio 1.08 (95% CI 1.02-1.14), a small relative difference
• Higher with estrogen-only for lupus, rheumatoid arthritis, psoriasis, psoriatic arthritis, MS and lichen sclerosus

Observational, so it can't show cause, and the absolute gap is small; the authors call it hypothesis-generating. The two groups may still differ in ways the matching can't capture.

Source: The Menopause Society, Oct 6, 2026

[Hormones] · News from Oct 6, 2026

TRT meta-analysis: better cholesterol, but an arrhythmia signal

A meta-analysis in Endocrine pooled 31 randomized trials of TRT vs placebo (9,437 middle-aged and older men with low or low-normal testosterone, 40 days to 36 months):

• Total cholesterol down about 10 mg/dL, LDL and triglycerides about 7, no significant HDL change
• About 67 seconds longer on a treadmill before ECG signs of ischemia, and slightly thinner carotid artery walls
• Higher odds of nonfatal arrhythmia (OR 1.58); the authors call its clinical significance uncertain

The search ended in July 2024. A separate review in the Journal of the Endocrine Society (Sept 2026) found the atrial fibrillation evidence mixed, with no proof that TRT causes it.

Source: Endocrine (Qin et al.), Oct 6, 2026

Our guides: Testosterone Cypionate

[Peptides] · News from Oct 6, 2026

WADA's 2027 banned list now names 'peptides' as prohibited

USADA's advisory on WADA's 2027 Prohibited List (in effect Jan 1, 2027) flags a change for tested athletes:

• 'Peptides' in general are now named as prohibited in class S0 (non-approved substances), banned at all times
• USADA lists BPC-157 and TB-500 among its examples of prohibited peptides
• A peptide not named on the list may still be prohibited, and banned ones may be sold under other names or slang terms
• Semaglutide and tirzepatide are in the monitoring program: labs track their use in and out of competition, but they are not banned

Bottom line: 'it's not on the list' is not a safe assumption.

Source: USADA athlete advisory, Oct 6, 2026

Our guides: Semaglutide · Tirzepatide · BPC-157 · TB-500

[GLP-1] · News from Oct 5, 2026

GLP-1s around conception: big review finds no clear rise in pregnancy risks

A review in Med of 10 studies (9 pooled) covering 2,118,215 pregnancies:

• 8,325 were exposed to a GLP-1 drug within six months before a positive pregnancy test
• No clearly detectable increase in miscarriage, stillbirth, birth defects or preterm birth
• Same for gestational diabetes, high blood pressure and excess weight gain
• Little data on individual drugs or on exposure later in pregnancy

All observational, so it can't prove safety; the authors say more research is needed. UK MHRA guidance still says to stop GLP-1s before a planned pregnancy.

Source: The Pharmaceutical Journal, Oct 5, 2026

[GLP-1] · News from Oct 5, 2026

Survodutide's Phase 3 SYNCHRONIZE-2 results in type 2 diabetes, published in NEJM

Boehringer Ingelheim's survodutide, a glucagon/GLP-1 dual agonist, in 755 adults with obesity or overweight and type 2 diabetes, 76 weeks:

• Counting everyone, even those who stopped: 9.8% weight loss on 6.0 mg, 8.2% on 3.6 mg, vs 3.9% on placebo
• Assuming everyone stayed on drug: up to 13.1% vs 3.1%
• HbA1c fell up to 1.21 points from 7.4%, vs 0.03 (on-drug estimate)
• 18% stopped over GI side effects (nausea, vomiting, diarrhea, constipation) vs 1.2% on placebo, mostly during dose increases

Peer-reviewed, placebo-controlled, no head-to-head vs approved drugs. Survodutide is investigational and not approved anywhere.

Source: BioPharm International, Oct 5, 2026